Worldwide, pulmonary arterial hypertension (PAH) affects more than 2 of every 100,000 females ages 15 to 49 — women…
Articles by Marisa Wexler, MS
The PAH Initiative is hosting video events in November to discuss the importance of shared decision making between doctors…
Allrock Bio has raised $50 million in financing to support the clinical development of pulmonary hypertension (PH) treatment ROC-101.
Japan’s Ministry of Health, Labour and Welfare (MHLW) has granted orphan drug designation to mosliciguat, an investigational inhalation therapy that…
United Therapeutics and Mannkind Corporation are teaming up to develop a new inhaled therapy for pulmonary hypertension.
At diagnosis, Black people with pulmonary arterial hypertension (PAH) tend to have more severe disease than their non-Black counterparts,…
A study found that changes in immune cell metabolism may underlie increases in inflammatory signaling molecules in people with…
The rates of long-term survival and perioperative complications after a lung transplant in people with group 2 or group 3…
A Phase 3 clinical trial testing the experimental daily oral treatment ralinepag in people with pulmonary arterial hypertension (PAH)…
Adding Winrevair (sotatercept-csrk) to background treatment significantly reduces the risk of clinical worsening in people with a recent…
Enrollment is now complete — with nearly 400 participants with pulmonary arterial hypertension (PAH) — in the Phase 3 PROSERA…
Adding more lines of treatment may reduce the risk of rehospitalization among adults with pulmonary arterial hypertension (PAH) who…